Navigation Links
Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidate Contrave(TM) and its effect on markers of cardiovascular disease (visceral fat, serum cholesterol, and triglycerides) and insulin-resistance. The findings come from additional analyses of the Phase IIb multi-center clinical trial of Contrave. The data will be presented on Saturday, June 23rd, 6:00-7:15 pm and Monday, June 25th, 2007 at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and Naltrexone Improves Markers of Insulin-Resistance."

Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel formulation of naltrexone SR in a single tri-layer tablet. In a Phase IIb multi-center clinical trial, Contrave demonstrated statistically significant weight loss at 24 weeks compared to bupropion SR alone, naltrexone IR (immediate release) alone, and placebo. Contrave is now being studied in two separate multi-center Phase III studies, one of which is designed to further assess its safety and efficacy in obese subjects with Type II diabetes.

About Orexigen Therapeutics

Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take ad
'"/>




Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis
Post Your Comments:
(Date:4/24/2015)... Introduction of new ... tools for radiosurgery/SBRT   The "Elements" ... enhancing the workflow for difficult to treat indications ... - comes full circle with the introduction of ... Elements enable on-the-fly generation of consistent treatment plans ...
(Date:4/24/2015)... Hi-Tech Pharmaceuticals refutes the results from ... of reliable scientific principles and methods and therefore ... of adulteration. The FDA is resting its very, ... misguided hope, that Methylphenylethylamine is not found in ... multiple other studies and cannot be relied on ...
(Date:4/24/2015)... , April 24, 2015 Hospira, ... in the development of biosimilar therapies, spoke about the ... at the European Generics Association (EGA) annual European Biosimilars ... The company also announced the publication of a ... to achieving the full promise of biosimilars." ...
Breaking Medicine Technology:Brainlab Introduces New Generation of VMAT* for Brain and Spine at 3rd ESTRO in Barcelona 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 2Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 3Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 4Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 5Hi-Tech Responds to "Bullying Tactics" Issued by FDA on Acacia Rigidula 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7
(Date:4/24/2015)... 24, 2015 As the nation recognizes ... unique sacrifices of these young men and women, the ... Veterans and their Families” presents a special training session ... to gain a better understanding of the effect of ... For those – civilian and military – who provide ...
(Date:4/24/2015)... TX (PRWEB) April 24, 2015 The Fastest ... Long, after their great success of the Xtreme Fat Loss ... industry. The fat loss blueprint that claims to help ... the attention of HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. ... shows that the creators spent years researching and experimenting with ...
(Date:4/24/2015)... On February 21st, 2015, Per Wickstrom had ... ItsNotAboutMe.TV contributor Karen Salkin at Durkin Entertainment’s EcoLuxe Lounge, ... addiction, of which Wickstrom is the founder. Making appearances ... the EcoLuxe Lounge is a gathering of some of ... products and services. Among the many roles that she ...
(Date:4/24/2015)... Carinsurancequotesinfo.com has released a new blog ... to qualify for auto insurance as a ... auto insurance online, without having to follow a special ... parents can reduce their auto insurance expenses. The tips ... explained. , Clients can now visit an insurance ...
(Date:4/24/2015)... 2015 Olive Fertility Centre is proud ... and co-director, has been honoured for his pioneering work ... of Hope Gala. , “We are very pleased ... who has been at the forefront of fertility research ... Séguin, Executive Director of Fertile Futures--a Canadian non-profit organization ...
Breaking Medicine News(10 mins):Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2Health News:Auto Insurance Discounts for Single Parents - How to Qualify for Low Rates 2Health News:Olive Fertility Centre Co-founder, Dr Al Yuzpe, Recognized as a Pioneer in Fertility Preservation 2
... the aftereffects of a chlorine gas disaster in a South ... to expect and how to prepare emergency response systems for ... The study is now available in the January 2009 issue ... , "This is one of the largest community exposures to ...
... symptoms are highly prevalent in different geographic populations ... the lives of those affected. Examples include GERD, ... These problems have an impact on the individual,s ... community-based research evaluating the impact of chronic gastrointestinal ...
... Multi-Serve Canisters Make it Easy to Mix with Water ... 2009 quickly approaches, Americans will begin making New Year,s ... According to this year,s survey from FranklinCovey Products ... licensee of consumer products for FranklinCovey Co, , ...
... Fisher Vista, LLC has reported,its seventh consecutive year of ... core product HRmarketer.com and strong demand for media,relations and ... The HRmarketer Services Group, established ... Services Group provides HR vendors with a,one-stop source for ...
... ARAY ), a global leader in the ... scheduled to present at the 11th Annual Needham Growth ... 2009 at 11:00 a.m. EST (8:00 a.m. PST).A live ... the investor relations page of the Company,s Web site ...
... Walks Drive Home Importance of Awareness and Education of ... effort to raise money for The Kidney TRUST(TM) -- ... chronic kidney disease (CKD) -- DaVita Inc., the nation,s ... the 3rd annual "Kidney Awareness Time(TM)" Walk-a-thon (The KAT ...
Cached Medicine News:Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 2Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 3Health News:Chronic gastrointestinal symptoms in Korean population 2Health News:Ocean Spray(R) Announces Sugar-Free Drink Mixes - A Sweet Way for Dieters to 'Stick' to Their Resolutions 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Accuray Incorporated to Present at 11th Annual Needham Growth Stock Conference 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 3